Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
September 07 2021 - 5:22PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company
focused on discovering, developing, and commercializing gene
therapies to cure blindness diseases and developing a vaccine to
fight COVID-19, today announced that it will be participating in
Citi’s 16th Annual BioPharma Virtual Conference being held on
September 8-10, 2021 and at the H.C. Wainwright Global Investment
Conference being held on September 13-15, 2021.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present
virtually at Citi’s conference and Sanjay Subramanian, CFO and Head
of Corporate Development will present virtually at H.C. Wainwright.
Both will provide updates on COVAXIN™, the investigational COVID-19
vaccine which the company is co-developing with Bharat Biotech for
the U.S. and Canadian markets. They will also present information
about Ocugen’s breakthrough modifier gene therapy platform, which
has generated product candidates that are expected to enter Phase
1/2a clinical trials in ophthalmic disease states over the next 18
months.
Citi/Ocugen Fireside
ChatDate/Time: Wednesday, September 8,
2021, from 3:15PM-4:00PM Eastern TimeRegistration
link:
https://kvgo.com/citi-16th-annual-biopharma-vc/ocugen-inc-sept-2021
H.C. Wainwright Global Investment
ConferenceDate/Time: Presentation
available on-demand starting at 7:00AM Eastern Time on September
13, 2021Registration link:
https://journey.ct.events/view/705764c5-88a7-4a4c-afff-d1688de5a5d9
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
developing a vaccine to save lives from COVID-19. Our breakthrough
modifier gene therapy platform has the potential to treat multiple
retinal diseases with one drug — “one to many,” and our novel
biologic product candidate aims to offer better therapy to patients
with underserved diseases such as wet age-related macular
degeneration, diabetic macular edema, and diabetic retinopathy. We
are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for
COVID-19 in the U.S. and Canadian markets. For more information,
please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations, such as risks and
uncertainties regarding market and other conditions and the timing
of our planned clinical trials. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result
of new information, future events or otherwise, after the date
of this press release.
Ocugen Contact:Ken InchaustiHead, Investor
Relations & CommunicationsIR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024